Introduction
For millions of American women, battling a chronic illness is only half the fight. The other half is convincing doctors, employers, and loved ones that the illness is real. The U.S. Department of Health and Human Services (HHS) is now stepping into that fight — putting so-called “invisible illnesses” at the center of a landmark national conversation on women’s health. At the inaugural HHS National Conference on Women’s Health, federal officials, researchers, and patient advocates gathered to shine a long-overdue light on conditions that remain hidden, misunderstood, and chronically underdiagnosed.
What Are Invisible Illnesses?
Defining Conditions That Defy Easy Detection
Invisible illnesses are chronic conditions whose symptoms are not immediately apparent to outside observers. Unlike a broken arm or visible rash, these disorders often produce debilitating fatigue, cognitive impairment, widespread pain, and systemic dysfunction — yet patients frequently appear fine on the surface.
This invisibility carries a steep social and medical cost. Many patients report being dismissed by physicians or told their symptoms are “all in their head.” Research shows that autoimmune patients see an average of six doctors over four years before receiving an accurate diagnosis. For conditions like Long COVID, fibromyalgia, and endometriosis, delayed diagnosis directly translates to delayed care and worsening outcomes.
Women bear a disproportionate share of this burden. Invisible illnesses, including ME/CFS, POTS, endometriosis, and Mast Cell Activation Syndrome (MCAS), affect women at far higher rates than men. Additionally, conditions such as fibromyalgia — which affects women overwhelmingly — were historically dismissed by the medical community as exaggerated or psychological.
The Inaugural HHS National Women’s Health Conference
A Historic Gathering in Washington, D.C.
The HHS National Conference on Women’s Health, presented by the Office on Women’s Health (OWH), took place on March 11–13, 2026, at the Omni Shoreham Hotel in Washington, D.C. It marked the first time HHS convened a dedicated national conference of this scale specifically focused on women’s health.
The conference brought together policymakers, clinicians, researchers, and patient advocates to explore breakthroughs in research, prevention, diagnosis, and treatment of health conditions affecting women across the lifespan. Organizers designed the event to bridge critical gaps between scientific evidence and real-world implementation — and to drive cross-sector innovation in modernizing patient care.
Who Attended and Why It Matters
Speakers included leading researchers and practitioners working on endometriosis, Long COVID, ME/CFS, and related chronic conditions. Experts such as microbiologist Dr. Amy Proal, known for her work linking infections to chronic illness, participated alongside gynecologic specialists, fertility researchers, and federal health officials. Their collective presence underscored that invisible illnesses are, at last, entering the mainstream of federal health policy.
Secretary Kennedy’s Call to Action
Bringing Invisible Illnesses “Out of the Shadows”
HHS Secretary Robert F. Kennedy, Jr. has made tackling invisible illnesses a stated priority of his tenure. At a Long COVID roundtable he convened, Kennedy declared: “We will bring invisible illnesses out of the shadows and restore hope to those affected.” His framing was deliberate — signaling that the federal government intends to treat these conditions with the same urgency as more visible public health crises.
Kennedy launched a Long COVID consortium and pledged ongoing coordination across agencies including NIH, ARPA-H, and FDA. Furthermore, his administration emphasized a disease-agnostic approach — recognizing that conditions like Long COVID, Lyme disease, and ME/CFS share overlapping mechanisms and deserve unified research infrastructure rather than siloed, condition-by-condition study.
Key Invisible Illnesses Disproportionately Affecting Women
Long COVID and ME/CFS
Long COVID affects an estimated 18 million U.S. adults, with women representing a disproportionate share. It is a multisystem condition producing fatigue, brain fog, cardiovascular issues, and respiratory symptoms. ME/CFS — Myalgic Encephalomyelitis/Chronic Fatigue Syndrome — shares substantial overlap with Long COVID and affects between 17 and 24 million people globally. Both conditions currently lack FDA-approved diagnostic tests, making clinical recognition a persistent challenge.
Endometriosis, POTS, and Fibromyalgia
Endometriosis affects approximately 190 million reproductive-age women worldwide. Despite causing severe pelvic pain, excessive bleeding, and infertility, it takes an average of seven to ten years to diagnose. POTS (Postural Orthostatic Tachycardia Syndrome) is frequently mistaken for anxiety, while fibromyalgia — characterized by widespread chronic pain — was long dismissed as non-existent before earning formal recognition as a diagnosis.
New HHS Initiatives Targeting Invisible Illnesses
From Awareness to Action
HHS announced several concrete steps following its roundtables and ahead of the women’s health conference. These include a national public awareness and education campaign to inform patients, families, and employers about invisible illnesses. Moreover, HHS plans to launch an online hub where physicians and researchers can share best practices for diagnosis and treatment.
LymeX, HHS’s public-private innovation accelerator for Lyme disease, also reflects this broader push. The agency further announced plans to develop living, dynamic evidence guidelines for infection-associated chronic illnesses — updated every six months as new research emerges.
Why This Moment Matters for Women’s Health
Closing the Gap Between Research and Recognition
Women have long faced a research gap in medicine. Many clinical studies historically excluded female participants, leaving physicians with incomplete data for diagnosing and treating conditions that affect women most. The HHS National Women’s Health Conference signals a meaningful course correction — one that centers women’s experiences, validates invisible suffering, and demands systemic change.
Patient advocates who have spent years fighting for recognition now see a federal platform validating their struggles. However, experts caution that sustained funding, robust infrastructure, and concrete research investment must follow the conference’s momentum. Awareness, while essential, is only the beginning.
For women living with invisible illnesses, this conference represents more than a policy event. It represents, finally, being seen.
